PA8654201A1 - Agentes citotóxicos que comprenden nuevos taxanos modificados en c-2 - Google Patents

Agentes citotóxicos que comprenden nuevos taxanos modificados en c-2

Info

Publication number
PA8654201A1
PA8654201A1 PA20058654201A PA8654201A PA8654201A1 PA 8654201 A1 PA8654201 A1 PA 8654201A1 PA 20058654201 A PA20058654201 A PA 20058654201A PA 8654201 A PA8654201 A PA 8654201A PA 8654201 A1 PA8654201 A1 PA 8654201A1
Authority
PA
Panama
Prior art keywords
cytotoxic agents
taxans
modified
new
therapeutic use
Prior art date
Application number
PA20058654201A
Other languages
English (en)
Inventor
Michael L Miller
Ravi V J Chari
Erkan Baloglu
Alain Commercon
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34931584&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PA8654201(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of PA8654201A1 publication Critical patent/PA8654201A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A NUEVOS AGENTES CITOTOXICOS Y SU UTILIZACION TERAPEUTICA. MAS ESPECIFICAMENTE, LA INVENCION SE REFIERE A NUEVOS AGENTES CITOTOXICOS QUE COMPRENDEN TAXANOS Y SU UTILIZACION TERAPEUTICA. ESTOS NUEVOS AGENTES CITOTOXICOS TIENEN UTILIZACION TERAPEUTICA COMO RESULTADO DE PROPORCIONAR LOS TAXANOS A UNA POBLACION CELULAR ESPECIFICA DE FORMA DIRIGIDA MEDIANTE ENLACE QUIMICO DEL TAXANO CON EL AGENTE DE UNION A LA CELULA.
PA20058654201A 2004-12-07 2005-12-01 Agentes citotóxicos que comprenden nuevos taxanos modificados en c-2 PA8654201A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04292899A EP1688415A1 (en) 2004-12-07 2004-12-07 Cytotoxic agents comprising new C-2 modified taxanes

Publications (1)

Publication Number Publication Date
PA8654201A1 true PA8654201A1 (es) 2006-07-03

Family

ID=34931584

Family Applications (2)

Application Number Title Priority Date Filing Date
PA20058654201A PA8654201A1 (es) 2004-12-07 2005-12-01 Agentes citotóxicos que comprenden nuevos taxanos modificados en c-2
PA20058654601A PA8654601A1 (es) 2004-12-07 2005-12-06 Agentes citotoxicos que comprenden taxanos nuevos

Family Applications After (1)

Application Number Title Priority Date Filing Date
PA20058654601A PA8654601A1 (es) 2004-12-07 2005-12-06 Agentes citotoxicos que comprenden taxanos nuevos

Country Status (12)

Country Link
US (1) US7598290B2 (es)
EP (2) EP1688415A1 (es)
JP (1) JP2008523020A (es)
AR (1) AR051785A1 (es)
AU (1) AU2005313445A1 (es)
CA (1) CA2614574A1 (es)
DO (1) DOP2005000243A (es)
PA (2) PA8654201A1 (es)
PE (1) PE20061063A1 (es)
TW (1) TW200640893A (es)
UY (1) UY29250A1 (es)
WO (1) WO2006061259A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7589180B2 (en) 2001-05-11 2009-09-15 Abbott Laboratories Inc. Specific binding proteins and uses thereof
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
US20090246211A1 (en) * 2005-05-12 2009-10-01 Henri John T Molecular constructs suitable for targeted conjugates
MX338185B (es) 2007-01-25 2016-04-05 Dana Farber Cancer Inst Inc Uso de anticuerpos anti-egfr en el tratamiento de enfermedad mediada por egfr mutante.
WO2008115404A1 (en) 2007-03-15 2008-09-25 Ludwing Institute For Cancer Research Treatment method using egfr antibodies and src inhibitors and related formulations
EP2188311B1 (en) 2007-08-14 2016-10-05 Ludwig Institute for Cancer Research Ltd. Monoclonal antibody 175 targeting the egf receptor and derivatives and uses thereof
MX341687B (es) 2010-02-10 2016-08-30 Immunogen Inc "anticuerpos cd20 y su utilización".
ES2602118T3 (es) 2010-12-09 2017-02-17 Immunogen, Inc. Métodos para la preparación de agentes de reticulación cargados
CA2891280C (en) 2012-11-24 2018-03-20 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
PT3122757T (pt) 2014-02-28 2023-11-03 Hangzhou Dac Biotech Co Ltd Ligantes carregados e as suas utilizações em conjugação
EP3319936A4 (en) 2015-07-12 2019-02-06 Suzhou M-conj Biotech Co., Ltd. PLACES OF CONDUCT FOR THE CONJUGATION OF CELL BINDING MOLECULES
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
JP7138350B2 (ja) 2016-11-14 2022-09-16 ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ． 共役連結体、該連結体を含有する細胞結合分子－薬物共役体、並びに該共役体及び連結体の使用及び製造方法
WO2022010797A2 (en) 2020-07-07 2022-01-13 Bionecure Therapeutics, Inc. Novel maytansinoids as adc payloads and their use for the treatment of cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703247A (en) * 1993-03-11 1997-12-30 Virginia Tech Intellectual Properties, Inc. 2-Debenzoyl-2-acyl taxol derivatives and methods for making same
NZ517772A (en) * 1999-11-24 2004-03-26 Immunogen Inc Cytotoxic agents comprising taxanes and their therapeutic use
IT1317731B1 (it) * 2000-01-18 2003-07-15 Indena Spa Tassani semisintetici con attivita' antitumorale ed antiangiogenetica.
US6596757B1 (en) * 2002-05-14 2003-07-22 Immunogen Inc. Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use
CA2494074A1 (en) * 2002-08-02 2004-02-12 Immunogen, Inc. Cytotoxic agents containing novel potent taxanes and their therapeutic use
EP1747209A4 (en) * 2004-05-14 2007-12-12 Immunogen Inc A SIMPLE METHOD OF SYNTHESIZING BACCATINE III COMPOUNDS

Also Published As

Publication number Publication date
EP1819687A2 (en) 2007-08-22
AR051785A1 (es) 2007-02-07
WO2006061259A2 (en) 2006-06-15
US7598290B2 (en) 2009-10-06
DOP2005000243A (es) 2006-11-30
PA8654601A1 (es) 2006-09-08
AU2005313445A1 (en) 2006-06-15
PE20061063A1 (es) 2006-11-06
TW200640893A (en) 2006-12-01
WO2006061259A3 (en) 2007-01-11
CA2614574A1 (en) 2006-06-15
JP2008523020A (ja) 2008-07-03
UY29250A1 (es) 2006-06-30
US20070270482A1 (en) 2007-11-22
EP1688415A1 (en) 2006-08-09

Similar Documents

Publication Publication Date Title
PA8654201A1 (es) Agentes citotóxicos que comprenden nuevos taxanos modificados en c-2
DOP2005000248A (es) Agentes citotoxicos que comprendentaxanos nuevos.
GT201000008A (es) Agentes citotoxicos que comprenden nuevos derivados de tomaimicina y su uso terapeutico
UY29086A1 (es) Nuevas composiciones farmacéuticas para el tratamiento de trastornos hiperproliferativos.
HN2008000188A (es) 7- aza- indazoles sustituidos, composiciones que los contienen, procedimiento de fabricacion y su utilizacion
UY33029A (es) Antagonistas de espiro-oxindol de mdm2
SV2009003393A (es) Polipeptidos de factor vii modificaciones y usos de los mismos
CU24349B1 (es) Composiciones que comprenden 2,3-dihidroimidazo [1,2-c] quinazolinas sustituidas útiles para el tratamiento del cáncer
GT201400043A (es) Imidazopiridazinas sustituidas con amino
CL2015002941A1 (es) Usos terapéuticos de empaglifozina
ECSP088298A (es) Modulacion de la expresion del receptor glucocorticoide
PA8778601A1 (es) Inhibidores de la unión entre hdm2 y el proteasoma
UY31816A (es) Agente para el tratamiento y/o prevención de una enfemedad autoinmune y para la formación de células t reguladoras
HN2005029978A (es) Formulaciones
CO6351786A2 (es) Inkibidores de la cinasa map p38
CL2009000816A1 (es) Metodos para modificar una estructura especifica asociada a una actividad biologica; ysu uso en el tratamiento de enfermedades y sintomas como son autoinmune, oculares, snc, cancer, entre otras.
ECSP109923A (es) Bromhidrato de bupropion y aplicaciones terapéuticas
AR114148A2 (es) Composición terapéutica saborizada basada en arcilla
AR083038A1 (es) Mejoras relativas a composiciones para el tratamiento de las telas, que comprenden agentes de beneficio dirigidos
UY29387A1 (es) Imidazoles sustituidos con heterociclilamida.
CO6700840A2 (es) Teobromina en combinación con un expectorante o un mucolítico para su uso en terapia
ECSP12012132A (es) Combinación de teobromina con un descongestivo y su uso para el tratamiento de la tos
CL2011000614A1 (es) Forma de dosificacion oral solida que comprende alisquireno solo o en combinacion con otro agente activo; proceso de preparacion; y uso en el tratamiento de enfermedades tales comohipertension, angina, ateroesclerosis, entre otras.
AR061618A1 (es) Formas de dosificacion unitaria de temozolomida
CR9486A (es) Composiciones y metodos para el diagnostico y tratamiento del tumor